Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Ionizing radiation reduces the capacity of activated macrophages to induce T-cell proliferation, but does not trigger dendritic cell-mediated non-targeted effects.

Wunderlich R, Rühle PF, Deloch L, Roedel F, Fietkau R, Gaipl US, Frey B.

Int J Radiat Biol. 2018 Jun 18:1-36. doi: 10.1080/09553002.2018.1490037. [Epub ahead of print]

PMID:
29912595
2.

Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies.

Rückert M, Deloch L, Fietkau R, Frey B, Hecht M, Gaipl US.

Strahlenther Onkol. 2018 Jun;194(6):509-519. doi: 10.1007/s00066-018-1287-1. Epub 2018 Mar 2. Review.

PMID:
29500551
3.

Impact of radon and combinatory radon/carbon dioxide spa on pain and hypertension: Results from the explorative RAD-ON01 study.

Rühle PF, Klein G, Rung T, Tiep Phan H, Fournier C, Fietkau R, Gaipl US, Frey B.

Mod Rheumatol. 2018 Mar 2:1-8. doi: 10.1080/14397595.2018.1442640. [Epub ahead of print]

PMID:
29451048
4.

Editorial: Radiation and the Immune System: Current Knowledge and Future Perspectives.

Lumniczky K, Candéias SM, Gaipl US, Frey B.

Front Immunol. 2018 Jan 23;8:1933. doi: 10.3389/fimmu.2017.01933. eCollection 2017. No abstract available.

5.

[Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy].

Hecht M, Gaipl US, Fietkau R.

Strahlenther Onkol. 2018 Mar;194(3):269-271. doi: 10.1007/s00066-017-1253-3. German. No abstract available.

PMID:
29374302
6.

Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases.

Frey B, Rückert M, Deloch L, Rühle PF, Derer A, Fietkau R, Gaipl US.

Immunol Rev. 2017 Nov;280(1):231-248. doi: 10.1111/imr.12572. Review.

PMID:
29027224
7.

Decrease of Markers Related to Bone Erosion in Serum of Patients with Musculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy.

Cucu A, Shreder K, Kraft D, Rühle PF, Klein G, Thiel G, Frey B, Gaipl US, Fournier C.

Front Immunol. 2017 Jul 25;8:882. doi: 10.3389/fimmu.2017.00882. eCollection 2017.

8.

Full Length Interleukin 33 Aggravates Radiation-Induced Skin Reaction.

Kurow O, Frey B, Schuster L, Schmitt V, Adam S, Hahn M, Gilchrist D, McInnes IB, Wirtz S, Gaipl US, Krönke G, Schett G, Frey S, Hueber AJ.

Front Immunol. 2017 Jun 28;8:722. doi: 10.3389/fimmu.2017.00722. eCollection 2017.

9.

Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial.

Rühle PF, Goerig N, Wunderlich R, Fietkau R, Gaipl US, Strnad A, Frey B.

Front Neurol. 2017 Jun 23;8:296. doi: 10.3389/fneur.2017.00296. eCollection 2017.

10.

Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases.

Rödel F, Fournier C, Wiedemann J, Merz F, Gaipl US, Frey B, Keilholz L, Seegenschmiedt MH, Rödel C, Hehlgans S.

Front Immunol. 2017 May 3;8:519. doi: 10.3389/fimmu.2017.00519. eCollection 2017. Review.

11.

Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors.

Frey B, Rückert M, Weber J, Mayr X, Derer A, Lotter M, Bert C, Rödel F, Fietkau R, Gaipl US.

Front Immunol. 2017 Mar 8;8:231. doi: 10.3389/fimmu.2017.00231. eCollection 2017.

12.

Modulation of the peripheral immune system after low-dose radon spa therapy: Detailed longitudinal immune monitoring of patients within the RAD-ON01 study.

Rühle PF, Wunderlich R, Deloch L, Fournier C, Maier A, Klein G, Fietkau R, Gaipl US, Frey B.

Autoimmunity. 2017 Mar;50(2):133-140. doi: 10.1080/08916934.2017.1284819. Epub 2017 Feb 21.

PMID:
28263099
13.

Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.

Eckert F, Gaipl US, Niedermann G, Hettich M, Schilbach K, Huber SM, Zips D.

Clin Transl Radiat Oncol. 2017 Feb 4;2:29-35. doi: 10.1016/j.ctro.2016.12.006. eCollection 2017 Feb. Review.

14.

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.

Derer A, Spiljar M, Bäumler M, Hecht M, Fietkau R, Frey B, Gaipl US.

Front Immunol. 2016 Dec 22;7:610. doi: 10.3389/fimmu.2016.00610. eCollection 2016.

15.

Interconnection between DNA damage, senescence, inflammation, and cancer.

Wunderlich R, Ruehle PF, Deloch L, Unger K, Hess J, Zitzelsberger H, Lauber K, Frey B, Gaipl US.

Front Biosci (Landmark Ed). 2017 Jan 1;22:348-369. Review.

PMID:
27814618
16.

Novel technique for high-precision stereotactic irradiation of mouse brains.

Hartmann J, Wölfelschneider J, Stache C, Buslei R, Derer A, Schwarz M, Bäuerle T, Fietkau R, Gaipl US, Bert C, Hölsken A, Frey B.

Strahlenther Onkol. 2016 Nov;192(11):806-814. Epub 2016 Jul 11.

PMID:
27402389
17.

Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.

Baues C, Semrau R, Gaipl US, Bröckelmann PJ, Rosenbrock J, Engert A, Marnitz S.

Strahlenther Onkol. 2017 Feb;193(2):95-99. doi: 10.1007/s00066-016-1050-4. Epub 2016 Oct 4.

PMID:
27704149
18.

Cancer Cell Death-Inducing Radiotherapy: Impact on Local Tumour Control, Tumour Cell Proliferation and Induction of Systemic Anti-tumour Immunity.

Frey B, Derer A, Scheithauer H, Wunderlich R, Fietkau R, Gaipl US.

Adv Exp Med Biol. 2016;930:151-72. doi: 10.1007/978-3-319-39406-0_7. Review.

PMID:
27558821
19.

Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry.

Rühle PF, Fietkau R, Gaipl US, Frey B.

Int J Mol Sci. 2016 Aug 11;17(8). pii: E1316. doi: 10.3390/ijms17081316.

20.

The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia.

Finkel P, Frey B, Mayer F, Bösl K, Werthmöller N, Mackensen A, Gaipl US, Ullrich E.

Oncoimmunology. 2016 Jun 7;5(6):e1101206. doi: 10.1080/2162402X.2015.1101206. eCollection 2016 Jun.

21.

Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation.

Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US.

Front Oncol. 2016 Jun 20;6:141. doi: 10.3389/fonc.2016.00141. eCollection 2016. Review.

22.

Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain.

Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, Dörfler A, Engelhorn T, Eyüpoglu I, Rühle PF, Putz F, Semrau S, Gaipl US, Fietkau R.

Neuro Oncol. 2016 Dec;18(12):1664-1672. Epub 2016 Jun 10.

23.

A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.

Kinzel L, Ernst A, Orth M, Albrecht V, Hennel R, Brix N, Frey B, Gaipl US, Zuchtriegel G, Reichel CA, Blutke A, Schilling D, Multhoff G, Li M, Niyazi M, Friedl AA, Winssinger N, Belka C, Lauber K.

Oncotarget. 2016 Jul 12;7(28):43199-43219. doi: 10.18632/oncotarget.9774.

24.

Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain : Correlation with neurological deterioration and improvement upon antiviral treatment.

Goerig N, Semrau S, Frey B, Korn K, Fleckenstein B, Überla K, Dörfler A, Putz F, Gaipl US, Fietkau R.

Strahlenther Onkol. 2016 Jul;192(7):489-97. doi: 10.1007/s00066-016-0987-7. Epub 2016 May 31.

PMID:
27245820
25.

[EGFR inhibition in NSCLC tumor cell lines : Influence on cell cycle and tumor control].

Gaipl US.

Strahlenther Onkol. 2016 Jun;192(6):425-7. doi: 10.1007/s00066-016-0977-9. German. No abstract available.

PMID:
27169393
26.

Erratum to: Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.

Muth C, Rubner Y, Semrau S, Rühle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US.

Strahlenther Onkol. 2016 Mar;192(3):156. doi: 10.1007/s00066-016-0942-7. No abstract available.

PMID:
26809739
27.

Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.

Werthmöller N, Frey B, Rückert M, Lotter M, Fietkau R, Gaipl US.

Int J Hyperthermia. 2016;32(1):23-30. doi: 10.3109/02656736.2015.1106011. Epub 2016 Jan 11.

PMID:
26754406
28.

Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.

Muth C, Rubner Y, Semrau S, Rühle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US.

Strahlenther Onkol. 2016 Mar;192(3):146-55. doi: 10.1007/s00066-015-0926-z. Epub 2015 Dec 8. Erratum in: Strahlenther Onkol. 2016 Mar;192(3):156.

PMID:
26646311
29.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

30.

Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors.

Derer A, Frey B, Fietkau R, Gaipl US.

Cancer Immunol Immunother. 2016 Jul;65(7):779-86. doi: 10.1007/s00262-015-1771-8. Epub 2015 Nov 21. Review.

PMID:
26590829
31.

Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications.

Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US.

Front Immunol. 2015 Oct 8;6:505. doi: 10.3389/fimmu.2015.00505. eCollection 2015. Review.

32.

The in vitro immunogenic potential of caspase-3 proficient breast cancer cells with basal low immunogenicity is increased by hypofractionated irradiation.

Kötter B, Frey B, Winderl M, Rubner Y, Scheithauer H, Sieber R, Fietkau R, Gaipl US.

Radiat Oncol. 2015 Sep 17;10:197. doi: 10.1186/s13014-015-0506-5.

33.

Radiotherapy for benign achillodynia. Long-term results of the Erlangen Dose Optimization Trial.

Ott OJ, Jeremias C, Gaipl US, Frey B, Schmidt M, Fietkau R.

Strahlenther Onkol. 2015 Dec;191(12):979-84. doi: 10.1007/s00066-015-0893-4. Epub 2015 Sep 14.

PMID:
26369640
34.

The Immune System in Cancer Prevention, Development and Therapy.

Candeias SM, Gaipl US.

Anticancer Agents Med Chem. 2016;16(1):101-7. Review.

PMID:
26299661
35.

Radio-immunotherapy: the focused beam expands.

Frey B, Gaipl US.

Lancet Oncol. 2015 Jul;16(7):742-3. doi: 10.1016/S1470-2045(15)00055-8. Epub 2015 Jun 18. No abstract available.

PMID:
26095779
36.

Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future.

Datta NR, Ordóñez SG, Gaipl US, Paulides MM, Crezee H, Gellermann J, Marder D, Puric E, Bodis S.

Cancer Treat Rev. 2015 Nov;41(9):742-53. doi: 10.1016/j.ctrv.2015.05.009. Epub 2015 May 27. Review.

PMID:
26051911
37.

Study of the anti-inflammatory effects of low-dose radiation: The contribution of biphasic regulation of the antioxidative system in endothelial cells.

Large M, Hehlgans S, Reichert S, Gaipl US, Fournier C, Rödel C, Weiss C, Rödel F.

Strahlenther Onkol. 2015 Sep;191(9):742-9. doi: 10.1007/s00066-015-0848-9. Epub 2015 Jun 8.

PMID:
26051282
38.
39.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

40.

Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial.

Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rödel C, Rödel F, Schütz M, Combs SE, Multhoff G.

Front Immunol. 2015 Apr 15;6:162. doi: 10.3389/fimmu.2015.00162. eCollection 2015. Review.

41.

Enhanced tumour regression in a patient of liposarcoma treated with radiotherapy and hyperthermia: Hint for dynamic immunomodulation by hyperthermia.

Datta NR, Grobholz R, Puric E, Bode-Lesniewska B, Lomax N, Khan S, Gaipl US, Fuchs B, Bodis S.

Int J Hyperthermia. 2015;31(5):574-7. doi: 10.3109/02656736.2015.1033482. Epub 2015 Apr 20. No abstract available.

PMID:
25893831
42.

Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases.

Frey B, Hehlgans S, Rödel F, Gaipl US.

Cancer Lett. 2015 Nov 28;368(2):230-7. doi: 10.1016/j.canlet.2015.04.010. Epub 2015 Apr 14. Review.

PMID:
25888451
43.

Apoptotic cell clearance and its role in the origin and resolution of chronic inflammation.

Muñoz LE, Berens C, Lauber K, Gaipl US, Herrmann M.

Front Immunol. 2015 Mar 25;6:139. doi: 10.3389/fimmu.2015.00139. eCollection 2015. No abstract available.

44.

Immunological aspects of radiotherapy.

Scheithauer H, Belka C, Lauber K, Gaipl US.

Radiat Oncol. 2014 Aug 20;9:185. doi: 10.1186/1748-717X-9-185. No abstract available.

45.

Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.

Gaipl US, Multhoff G, Scheithauer H, Lauber K, Hehlgans S, Frey B, Rödel F.

Immunotherapy. 2014;6(5):597-610. doi: 10.2217/imt.14.38. Review.

PMID:
24896628
46.
47.

Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.

Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, Frey B, Fietkau R, Gaipl US.

Radiat Oncol. 2014 Mar 30;9(1):89. doi: 10.1186/1748-717X-9-89.

48.

Radiotherapy for benign calcaneodynia: long-term results of the Erlangen Dose Optimization (EDO) trial.

Ott OJ, Jeremias C, Gaipl US, Frey B, Schmidt M, Fietkau R.

Strahlenther Onkol. 2014 Jul;190(7):671-5. doi: 10.1007/s00066-014-0618-0. Epub 2014 Mar 26.

PMID:
24668250
49.

The Erlangen Dose Optimization Trial for radiotherapy of benign painful shoulder syndrome. Long-term results.

Ott OJ, Hertel S, Gaipl US, Frey B, Schmidt M, Fietkau R.

Strahlenther Onkol. 2014 Apr;190(4):394-8. doi: 10.1007/s00066-013-0520-1. Epub 2014 Feb 7. Erratum in: Strahlenther Onkol. 2014 Jun;190(6):605.

PMID:
24638241
50.

Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells.

Kulzer L, Rubner Y, Deloch L, Allgäuer A, Frey B, Fietkau R, Dörrie J, Schaft N, Gaipl US.

J Immunotoxicol. 2014 Oct;11(4):328-36. doi: 10.3109/1547691X.2014.880533. Epub 2014 Feb 10.

PMID:
24512329

Supplemental Content

Loading ...
Support Center